Cracker - you gotta wonder what 's going on with Tvec at Amgen. Since buying Biovex they've seen Zelboraf and Yervoy and now Tafinlar and Mekinist approved based on solid results. I guess we'll know in a few days when they present Tvec results at ASCO. But once again I note that the birnam wood of biotech is moving.
to me, t vec and successes for other oncology drugs tells me two things - that oncology may actually be the wave of the future in cancer research (obv. great for oncy) but also that competition has vastly increased. The projections of $100/share that is frequently shown around here may be a little bit delusional.